624 related articles for article (PubMed ID: 25897204)
1. Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome.
Tomatsu S; Sawamoto K; Alméciga-Díaz CJ; Shimada T; Bober MB; Chinen Y; Yabe H; Montaño AM; Giugliani R; Kubaski F; Yasuda E; Rodríguez-López A; Espejo-Mojica AJ; Sánchez OF; Mason RW; Barrera LA; Mackenzie WG; Orii T
Drug Des Devel Ther; 2015; 9():1937-53. PubMed ID: 25897204
[TBL] [Abstract][Full Text] [Related]
2. Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management.
Sawamoto K; Álvarez González JV; Piechnik M; Otero FJ; Couce ML; Suzuki Y; Tomatsu S
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102177
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy in newborn mucopolysaccharidosis IVA mice: early treatment rescues bone lesions?
Tomatsu S; Montaño AM; Oikawa H; Dung VC; Hashimoto A; Oguma T; Gutiérrez ML; Takahashi T; Shimada T; Orii T; Sly WS
Mol Genet Metab; 2015 Feb; 114(2):195-202. PubMed ID: 24953405
[TBL] [Abstract][Full Text] [Related]
4. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment.
Tomatsu S; Montaño AM; Oikawa H; Smith M; Barrera L; Chinen Y; Thacker MM; Mackenzie WG; Suzuki Y; Orii T
Curr Pharm Biotechnol; 2011 Jun; 12(6):931-45. PubMed ID: 21506915
[TBL] [Abstract][Full Text] [Related]
5. Development of Substrate Degradation Enzyme Therapy for Mucopolysaccharidosis IVA Murine Model.
Sawamoto K; Tomatsu S
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450640
[TBL] [Abstract][Full Text] [Related]
6. Long-term therapeutic efficacy of allogenic bone marrow transplantation in a patient with mucopolysaccharidosis IVA.
Chinen Y; Higa T; Tomatsu S; Suzuki Y; Orii T; Hyakuna N
Mol Genet Metab Rep; 2014; 1():31-41. PubMed ID: 25593792
[TBL] [Abstract][Full Text] [Related]
7. Activity of daily living in mucopolysaccharidosis IVA patients: Evaluation of therapeutic efficacy.
Chen H; Khan S; Celik B; Suzuki Y; Ago Y; Tomatsu S
Mol Genet Genomic Med; 2021 Nov; 9(11):e1806. PubMed ID: 34623762
[TBL] [Abstract][Full Text] [Related]
8. Enzyme replacement therapy in a murine model of Morquio A syndrome.
Tomatsu S; Montaño AM; Ohashi A; Gutierrez MA; Oikawa H; Oguma T; Dung VC; Nishioka T; Orii T; Sly WS
Hum Mol Genet; 2008 Mar; 17(6):815-24. PubMed ID: 18056156
[TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice.
Dvorak-Ewell M; Wendt D; Hague C; Christianson T; Koppaka V; Crippen D; Kakkis E; Vellard M
PLoS One; 2010 Aug; 5(8):e12194. PubMed ID: 20808938
[TBL] [Abstract][Full Text] [Related]
10. Plasma Proteomic Analysis in Morquio A Disease.
Álvarez JV; Bravo SB; Chantada-Vázquez MP; Barbosa-Gouveia S; Colón C; López-Suarez O; Tomatsu S; Otero-Espinar FJ; Couce ML
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34200496
[TBL] [Abstract][Full Text] [Related]
11. The characterisation of pulmonary function in patients with mucopolysaccharidoses IVA: A longitudinal analysis.
Kenth JJ; Thompson G; Fullwood C; Wilkinson S; Jones S; Bruce IA
Mol Genet Metab Rep; 2019 Sep; 20():100487. PubMed ID: 31341787
[TBL] [Abstract][Full Text] [Related]
12. Characterization of New Proteomic Biomarker Candidates in Mucopolysaccharidosis Type IVA.
Álvarez VJ; Bravo SB; Chantada-Vazquez MP; Colón C; De Castro MJ; Morales M; Vitoria I; Tomatsu S; Otero-Espinar FJ; Couce ML
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33379360
[TBL] [Abstract][Full Text] [Related]
13. A Case Report of a Japanese Boy with Morquio A Syndrome: Effects of Enzyme Replacement Therapy Initiated at the Age of 24 Months.
Nakamura-Utsunomiya A; Nakamae T; Kagawa R; Karakawa S; Sakata S; Sakura F; Tani C; Matsubara Y; Ishino T; Tajima G; Okada S
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32024277
[TBL] [Abstract][Full Text] [Related]
14. Therapies of mucopolysaccharidosis IVA (Morquio A syndrome).
Tomatsu S; Alméciga-Díaz CJ; Barbosa H; Montaño AM; Barrera LA; Shimada T; Yasuda E; Mackenzie WG; Mason RW; Suzuki Y; Orii KE; Orii T
Expert Opin Orphan Drugs; 2013 Oct; 1(10):805-818. PubMed ID: 25419501
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Human Recombinant N-Acetylgalactosamine-6-Sulfate Sulfatase Produced in Pichia pastoris as Potential Enzyme for Mucopolysaccharidosis IVA Treatment.
Rodríguez-López A; Pimentel-Vera LN; Espejo-Mojica AJ; Van Hecke A; Tiels P; Tomatsu S; Callewaert N; Alméciga-Díaz CJ
J Pharm Sci; 2019 Aug; 108(8):2534-2541. PubMed ID: 30959056
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and effects of enzyme replacement therapy with elosulfase alfa in Korean patients with mucopolysaccharidosis type IVA.
Lee SH; Kim HY; Cho TJ; Kim H; Ko JM
Mol Genet Metab Rep; 2022 Jun; 31():100869. PubMed ID: 35782601
[TBL] [Abstract][Full Text] [Related]
17. [Mucopolysaccharidosis IVA (Morquio A syndrome): clinical, biological and therapeutic aspects].
Bouzidi H; Khedhiri S; Laradi S; Ferchichi S; Daudon M; Miled A
Ann Biol Clin (Paris); 2007; 65(1):5-11. PubMed ID: 17264033
[TBL] [Abstract][Full Text] [Related]
18. Elosulfase Alfa: a review of its use in patients with mucopolysaccharidosis type IVA (Morquio A syndrome).
Lyseng-Williamson KA
BioDrugs; 2014 Oct; 28(5):465-75. PubMed ID: 25200032
[TBL] [Abstract][Full Text] [Related]
19. Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance.
Akyol MU; Alden TD; Amartino H; Ashworth J; Belani K; Berger KI; Borgo A; Braunlin E; Eto Y; Gold JI; Jester A; Jones SA; Karsli C; Mackenzie W; Marinho DR; McFadyen A; McGill J; Mitchell JJ; Muenzer J; Okuyama T; Orchard PJ; Stevens B; Thomas S; Walker R; Wynn R; Giugliani R; Harmatz P; Hendriksz C; Scarpa M; ;
Orphanet J Rare Dis; 2019 Jun; 14(1):137. PubMed ID: 31196221
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
